Cubist Systematic Strategies LLC Grows Position in Jazz Pharmaceuticals PLC (JAZZ)

Cubist Systematic Strategies LLC increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 115.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,452 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,387 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Jazz Pharmaceuticals PLC were worth $692,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of JAZZ. Parametric Portfolio Associates LLC increased its stake in Jazz Pharmaceuticals PLC by 23.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 28,466 shares of the specialty pharmaceutical company’s stock worth $4,131,000 after purchasing an additional 5,427 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Jazz Pharmaceuticals PLC by 43.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after purchasing an additional 295 shares in the last quarter. Victory Capital Management Inc. increased its stake in Jazz Pharmaceuticals PLC by 1,074.9% in the 1st quarter. Victory Capital Management Inc. now owns 3,278 shares of the specialty pharmaceutical company’s stock worth $476,000 after purchasing an additional 2,999 shares in the last quarter. Alliancebernstein L.P. increased its stake in Jazz Pharmaceuticals PLC by 19.4% in the 1st quarter. Alliancebernstein L.P. now owns 4,211 shares of the specialty pharmaceutical company’s stock worth $611,000 after purchasing an additional 684 shares in the last quarter. Finally, United Services Automobile Association purchased a new position in Jazz Pharmaceuticals PLC in the 1st quarter worth about $697,000. 87.91% of the stock is currently owned by hedge funds and other institutional investors.

In other Jazz Pharmaceuticals PLC news, SVP Paul Treacy sold 1,304 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $143.32, for a total value of $186,889.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total value of $150,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,517 shares of company stock valued at $665,623. Corporate insiders own 4.30% of the company’s stock.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 3.26% during midday trading on Friday, hitting $133.95. The company had a trading volume of 775,450 shares. The firm has a market capitalization of $8.05 billion, a P/E ratio of 20.63 and a beta of 1.05. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75. The firm’s 50-day moving average is $147.15 and its 200-day moving average is $151.23.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.85 by ($0.13). The company had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.67 earnings per share. On average, analysts predict that Jazz Pharmaceuticals PLC will post $10.89 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Cubist Systematic Strategies LLC Grows Position in Jazz Pharmaceuticals PLC (JAZZ)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/28/jazz-pharmaceuticals-plc-jazz-shares-bought-by-cubist-systematic-strategies-llc.html.

A number of equities analysts recently weighed in on JAZZ shares. Deutsche Bank AG reissued a “buy” rating and issued a $176.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, July 4th. Janney Montgomery Scott lifted their price target on Jazz Pharmaceuticals PLC from $138.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, July 4th. Leerink Swann lifted their price target on Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, July 4th. Mizuho cut Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $162.00 to $150.00 in a research note on Tuesday, July 4th. Finally, Cowen and Company reissued a “buy” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $180.88.

Jazz Pharmaceuticals PLC Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply